The first children have been vaccinated in Scandinavian Biopharma's large Phase IIb study in The Gambia
The first child has been vaccinated in The Gambia with the company's ETEC vaccine candidate, ETVAX®. It is a randomised, placebo-controlled, and double-blind phase IIb study. The study will include about 5,000 children aged 6-23 months. The overall goal of the study is to investigate the protective effect against moderate to severe diarrhoea caused by ETEC over a 1- to 2-year period.